(ITOS) – Company Press Releases
-
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
-
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
-
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
-
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
-
iTeos to Participate in Upcoming Investor Conferences
-
iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
-
iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
-
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
-
NCR Atleos Set to Join S&P SmallCap 600
-
iTeos to Participate in Upcoming Investor Conferences
-
iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates
-
iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
-
iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
-
iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
-
iTeos to Present at Cowen 43rd Annual Health Care Conference
-
iTeos to Present at Cowen 43rd Annual Health Care Conference
-
iTeos to Present at SVB Securities Global Biopharma Conference
-
iTeos to Present at SVB Securities Global Biopharma Conference
-
iTeos Provides Business Updates and Clinical Development Plans for 2023
-
iTeos Provides Business Updates and Clinical Development Plans for 2023
-
iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
-
iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
-
iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update
-
iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update
-
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
-
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
-
Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer
-
iTeos Reports First Quarter 2022 Financial Results and Provides Business Update
-
iTeos Reports First Quarter 2022 Financial Results and Provides Business Update
-
Innoskel Appoints Dr Michel Detheux as Chairman
-
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
-
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
-
iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
iTeos to Present at the Cowen 42nd Annual Health Care Conference
-
iTeos to Present at the Cowen 42nd Annual Health Care Conference
-
iTeos to Participate in Upcoming Investor Conferences in February
-
iTeos to Participate in Upcoming Investor Conferences in February
-
iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer
-
iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer
-
iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
iTeos Therapeutics Set to Join S&P SmallCap 600
-
iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021
-
iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021
Back to ITOS Stock Lookup